Version history

{
  "session_id": "sess_SDA-2026-04-13-gap-debate-20260411-064946-4940f331_20260414-010720",
  "round_number": 4,
  "agent_persona": "persona-synthesizer",
  "agent_backend": "minimax/MiniMax-M2.7",
  "action": "synthesize",
  "content": "\n\n```json\n{\n  \"ranked_hypotheses\": [\n    {\n      \"rank\": 1,\n      \"title\": \"Peripheral IL-1β Primes Monocyte VLA-4 Activation via Inside-Out Signaling\",\n      \"mechanism\": \"IL-1β signaling through IL-1R1 on circulating monocytes drives inside-out activation of VLA-4, increasing affinity for VCAM-1 on activated brain microvascular endothelium and enabling firm adhesion and diapedesis.\",\n      \"target_gene\": \"IL1R1 / ITGA4\",\n      \"confidence_score\": 0.75,\n      \"novelty_score\": 0.55,\n      \"feasibility_score\": 0.80,\n      \"impact_score\": 0.85,\n      \"composite_score\": 0.745,\n      \"testable_prediction\": \"Anakinra treatment in EAE or AD models will reduce monocyte CNS infiltration by >50% as measured by flow cytometry, with corresponding behavioral improvement.\",\n      \"skeptic_concern\": \"Mechanistic chain from IL-1R1 to integrin activation is underspecified; MyD88/NF-κB transcriptional pathway may not explain rapid VLA-4 conformational change.\"\n    },\n    {\n      \"rank\": 2,\n      \"title\": \"Chemokine Receptor Redundancy in Monocyte CNS Trafficking\",\n      \"mechanism\": \"Monocyte CNS infiltration employs parallel CCR2/CCL2 and CX3CR1/CX3CL1 pathways, where blockade of either receptor alone is compensated by the other, explaining incomplete therapeutic efficacy of single-target approaches.\",\n      \"target_gene\": \"CCR2 / CX3CR1\",\n      \"confidence_score\": 0.60,\n      \"novelty_score\": 0.75,\n      \"feasibility_score\": 0.55,\n      \"impact_score\": 0.70,\n      \"composite_score\": 0.655,\n      \"testable_prediction\": \"Dual CCR2/CX3CR1 knockout mice will show >80% reduction in CNS monocyte accumulation compared to single knockout mice in EAE.\",\n      \"skeptic_concern\": \"Receptor redundancy hypothesis is supported by indirect evidence but lacks direct in vivo trafficking visualization data.\"\n    },\n    {\n      \"rank\": 3,\n      \"title\": \"Endothelial VCAM-1 Upregulation as Rate-Limiting Step\",\n      \"mechanism\": \"Brain microvascular endothelial cell activation by peripheral cytokines (IL-1β, TNF-α) induces VCAM-1 expression that serves as the rate-limiting adhesion step for monocyte capture, making endothelial VCAM-1 a critical therapeutic target.\",\n      \"target_gene\": \"VCAM1\",\n      \"confidence_score\": 0.65,\n      \"novelty_score\": 0.70,\n      \"feasibility_score\": 0.50,\n      \"impact_score\": 0.60,\n      \"composite_score\": 0.63,\n      \"testable_prediction\": \"Endothelial-specific VCAM-1 knockdown using AAV vectors will reduce monocyte CNS infiltration by >70% without affecting peripheral immune function.\",\n      \"skeptic_concern\": \"Endothelial targeting approaches face delivery challenges across the blood-brain barrier and may have narrower therapeutic windows.\"\n    }\n  ],\n  \"consensus_points\": [\n    \"Peripheral IL-1β plays a substantive role in driving monocyte trafficking to the CNS, supported by in vitro adhesion assays and IL-1R1 knockout mouse data.\",\n    \"The VLA-4/VCAM-1 axis is a validated molecular mechanism for monocyte firm adhesion, with natalizumab providing human proof-of-concept.\",\n    \"Targeted modulation of trafficking pathways represents the most promising therapeutic strategy for neuroinflammation.\"\n  ],\n  \"dissent_points\": [\n    \"Skeptic challenges whether IL-1R1/MyD88 signaling can directly drive rapid inside-out integrin activation, noting the canonical pathway is transcriptional; Theorist asserts β-arrestin/FAK coupling as alternative mechanism but evidence remains thin.\"\n  ],\n  \"debate_summary\": \"The debate converged on IL-1β/VLA-4 axis as the highest-priority therapeutic target, with the Skeptic correctly identifying a mechanistic gap in the intracellular cascade linking IL-1R1 activation to integrin conformational change, while the Expert emphasized clinical translatability and drug repurposing opportunities with Anakinra and Natalizumab.\"\n}\n```",
  "tokens_used": "955"
}